Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, randomized, multi-center comparative 2-arm trial of efficacy and safety of zoledronic acid (every 3-months vs. every 4 weeks) beyond approximately 1 year of treatment with zoledronic acid in patients with bone lesions from breast cancer.

X
Trial Profile

A prospective, randomized, multi-center comparative 2-arm trial of efficacy and safety of zoledronic acid (every 3-months vs. every 4 weeks) beyond approximately 1 year of treatment with zoledronic acid in patients with bone lesions from breast cancer.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Advanced breast cancer; Bone metastases
  • Focus Therapeutic Use
  • Acronyms ZOOM
  • Sponsors Novartis
  • Most Recent Events

    • 15 May 2013 Results published in Lancet Oncology.
    • 20 Jun 2012 Actual patient number changed to 425 as reported in results presented at ASCO 2012.
    • 05 Jun 2012 Primary endpoint 'Skeletal-event-rate' has been met; the experimental treatment regimen was found to be non-inferior to conventional treatment.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top